Four cases of disseminated mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma

Southern Medical Journal

Volumn 101, Issue 1, 2008, Pages 91-95

  Nadasy, Krisztina A ^a   Patel, Rikin S ^a   Emmett, Michael ^a   Murillo, Ricardo A ^a   Tribble, Marc A ^a   Black, Robert D ^a   Sutker, William L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antituberculous agents; Bacillus Calmette Gu rin (BCG); Bladder carcinoma; Granuloma; Mycobacterium bovis

Indexed keywords

AMIKACIN; BCG VACCINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RIFAMPICIN;

ADULT; AGED; ANAMNESIS; ARTICLE; BACTERIAL INFECTION; BLADDER CARCINOMA; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOMEGALOVIRUS INFECTION; DRUG INSTILLATION; DYSPNEA; EPSTEIN BARR VIRUS; FEVER; GRANULOMATOUS INFLAMMATION; HUMAN; HYPOXEMIA; LUNG GRANULOMA; LYMPHADENOPATHY; MALAISE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NIGHT SWEAT; OXYGEN THERAPY; PANCYTOPENIA; SEPSIS; SPLENOMEGALY; TRANSBRONCHIAL BIOPSY; UROGENITAL TRACT TUMOR;

AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; GRANULOMA; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; MYCOBACTERIUM INFECTIONS; NECROSIS; NEOPLASM RECURRENCE, LOCAL; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 37849005775     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31815d4047     Document Type: Article

References (11)

1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183.
2. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 2002;44:81-102.
3. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):S86-S90.
4. Prescott S, Jackson AM, Hawkyard SJ, et al. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis 2000;31(Suppl 3):S91-S93.
5. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
6. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140-148.
7. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565-572.
8. Van Outryve SM, Francque SM, Gentens PA, et al. Bacillus Calmette-Guerin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. Eur J Gastroenterol Hepatol 2004;16:1027-1032.
9. Suzuki S, Shinohara N, Harabayashi T, et al. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 2002;7:289-293.
10. Durek C, Rusch-Gerdes S, Jocham D, et al. Sensitivity of BCG to modern antibiotics. Eur Urol 2000;37(Suppl 1):21-25.
11. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935-939.